4//SEC Filing
Carr Daniel B 4
Accession 0001209191-10-036985
CIK 0000050710other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 3:23 PM ET
Size
28.5 KB
Accession
0001209191-10-036985
Insider Transaction Report
Form 4
Carr Daniel B
DirectorSee Remarks
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2010-07-02−95,000Exercise: $4.98Exp: 2017-01-03→ Common Stock (95,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2010-07-02−140,000Exercise: $3.53Exp: 2018-01-09→ Common Stock (140,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2010-07-02−89,826Exercise: $1.07Exp: 2019-01-23→ Common Stock (89,826 underlying) - Disposition to Issuer
Stock Option (right to buy)
2010-07-02−125,000Exercise: $4.05Exp: 2016-03-08→ Common Stock (125,000 underlying) - Disposition to Issuer
Stock Option (right to but)
2010-07-02−25,000Exercise: $3.11From: 2009-05-28Exp: 2018-05-28→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2010-07-02−119,885Exercise: $1.26Exp: 2019-05-01→ Common Stock (119,885 underlying) - Disposition to Issuer
Deferred Stock Units
2010-07-02$2.20/sh−59,524$130,953→ 0 total - Disposition from Tender
Common Stock
2010-06-30$2.20/sh−80,494$177,087→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2010-07-02−916,570Exercise: $1.96Exp: 2014-09-07→ Common Stock (916,570 underlying) - Disposition to Issuer
Stock Option (right to buy)
2010-07-02−12,500Exercise: $2.70Exp: 2015-04-12→ Common Stock (12,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2010-07-02−47,950Exercise: $1.15Exp: 2019-03-16→ Common Stock (47,950 underlying)
Footnotes (15)
- [F1]Pursuant to the Agreement and Plan of Merger, dated April 17, 2010, by and among Hospira, Inc., Discus Acquisition Corporation ("Purchaser") and Javelin Pharmaceuticals, Inc. (the "Company"), Purchaser merged with and into the Company on July 2, 2010 (the "Merger"). These shares, which were outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were immediately canceled and converted at the effective time of the Merger into the right to receive cash consideration equal to $2.20 per share.
- [F10]These options, which were outstanding, unexercised and fully vested immediately prior to the Effective Time were immediately canceled, terminated and converted into the right to receive a cash payment of $101,503.38, representing (a) the difference between the exercise price of the option and the merger consideration of $2.20 per share multiplied by (b) the number of shares subject to the option.
- [F11]These options vest in 3 equal annual installments beginning after 1/23/2010.
- [F12]These options, which were outstanding, unexercised and fully vested immediately prior to the Effective Time were immediately canceled, terminated and converted into the right to receive a cash payment of $50,347.50, representing (a) the difference between the exercise price of the option and the merger consideration of $2.20 per share multiplied by (b) the number of shares subject to the option.
- [F13]These options vest in 3 equal annual installments beginning after 3/16/2010.
- [F14]These options, which were outstanding, unexercised and fully vested immediately prior to the Effective Time were immediately canceled, terminated and converted into the right to receive a cash payment of $112,691.90, representing (a) the difference between the exercise price of the option and the merger consideration of $2.20 per share multiplied by (b) the number of shares subject to the option.
- [F15]These options vest in 2 equal installments on the first and second anniversary of the grant date.
- [F2]These Deferred Stock Units, which were outstanding and unexercised immediately prior to the Effective Time, accelerated and were immediately canceled, terminated and converted into the right to receive a cash payment equal to $2.20 per share.
- [F3]These options, which were outstanding, unexercised and fully vested immediately prior to the Effective Time were immediately canceled, terminated and converted into the right to receive a cash payment of $219,976.80, representing (a) the difference between the exercise price of the option and the merger consideration of $2.20 per share multiplied by (b) the number of shares subject to the option.
- [F4]These options vest in 3 equal annual installments beginning after 9/7/2005.
- [F5]These options, which were outstanding and unexercised immediately prior to the Effective Time were immediately canceled and terminated.
- [F6]These options vest in 3 equal annual installments beginning after 4/12/2006.
- [F7]These options vest in 3 equal annual installments beginning after 3/7/2007.
- [F8]These options vest in 3 equal annual installments beginning after 1/3/2008.
- [F9]These options vest in 3 equal annual installments beginning after 1/9/2009.
Documents
Issuer
JAVELIN PHARMACEUTICALS, INC
CIK 0000050710
Entity typeother
Related Parties
1- filerCIK 0001311634
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 3:23 PM ET
- Size
- 28.5 KB